Results 1 to 10 of about 8,113 (209)

Early Administration of Bosentan in High‐Risk COVID‐19 Outpatients at Risk of Sarcopenia: A Randomized, Double‐Blind, Placebo‐Controlled Trial [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Endothelial damage induces myofibrillar breakdown and muscle degradation in COVID‐19 infection. There is a relationship between increased endothelin‐1 synthesis and sarcopenia. We evaluated the preventive effect of early bosentan therapy as an
Shaahin Shahbazi, Erfan Shahbazi, Farid Zayeri, Zahra Vahdat Shariatpanahi   +3 more
doaj   +3 more sources

Nephroprotective Effect of Bosentan in Diabetic Rats

Journal of Cardiovascular Pharmacology, 2003
Previous studies have suggested that endothelins could be involved in the pathogenesis of target organ damage in diabetes. The aim of this study was to evaluate the possible protective effect of Bosentan, an antagonist of endothelin receptor, on the kidney of diabetic rats.
Alessandro Cosenzi, Elena Bernobich, Roberto Trevisan, Neva Milutinovic, Annamaria Borri, Giuseppe Bellini   +5 more
openalex   +5 more sources

Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers [PDF]

Scientific Reports
Bosentan is a drug used to treat pulmonary hypertension via dual endothelial receptor antagonism. Bosentan has a restricted oral bioavailability, a problem that's mostly due to poor solubility and hepatic metabolism.
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby   +3 more
doaj   +2 more sources

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial [PDF]

BMC Pediatrics
Background Access to inhaled nitric oxide (iNO) is limited in low resource settings due to non-availability and high cost. There is a need for research on low-cost alternative therapies for management of persistent pulmonary hypertension of the newborn ...
Aditya Kallimath, Sujata Deshpande, Pari Singh, Reema Garegrat, Satyan Lakshminrusimha, Rajesh Maheshwari, Pradeep Suryawanshi   +6 more
doaj   +2 more sources

Studies on the Vitrified and Cryomilled Bosentan [PDF]

Molecular Pharmaceutics, 2021
In this paper, several experimental techniques [X-ray diffraction, differential scanning calorimetry (DSC), thermogravimetry, Fourier transform infrared spectroscopy, and broad-band dielectric spectroscopy] have been applied to characterize the structural and thermal properties, H-bonding pattern, and molecular dynamics of amorphous bosentan (BOS ...
Aldona Minecka, Krzysztof Chmiel, Karolina Jurkiewicz, Barbara Hachuła, Rafał Łunio, Daniel Żakowiecki, Kinga Hyla, Bartłomiej Milanowski, Kajetan Koperwas, Kamil Kamiński, Marian Paluch, Ewa Kamińska   +11 more
openaire   +4 more sources

D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension [PDF]

Advanced Pharmaceutical Bulletin, 2016
Purpose: Bosentan is a drug currently taken orally for the treatment of pulmonary arterialhypertension. However, the water solubility of bosentan is very low, resulting in lowbioavailability.
Elham Ghasemian, Parisa Motaghian, Alireza Vatanara   +2 more
doaj   +1 more source

Bosentan monohydrate [PDF]

Acta Crystallographica Section E Structure Reports Online, 2012
In the title compound, C27H29N5O6S·H2O {systematic name: 4-tert-butyl-N-[6-(2-hy-droxy-eth-oxy)-5-(2-meth-oxy-phen-oxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide monohydrate], the dihedral angle between the mean planes of the pyrimidine rings is 27.0 (1)°.
Kaur, Manpreet, Jasinski, Jerry P., Keeley, Amanda C., Yathirajan, H. S., Betz, Richard, Gerber, Thomas, Butcher, Ray J.   +6 more
openaire   +4 more sources

Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study

Pulmonary Therapy, 2023
Introduction Real-world data on the comparative effectiveness of endothelin receptor antagonists (ERAs; macitentan, bosentan, ambrisentan) for pulmonary arterial hypertension (PAH), particularly in Asian countries, are scarce.
Junichi Omura, Yogeshwar Makanji, Nobuhiro Tanabe, Dae Young Yu, Jin Yu Tan, Sooyeol Lim, Mahsa H. Kouhkamari, Jeremy Casorso, David Bin-Chia Wu, Paul Bloomfield   +9 more
doaj   +1 more source

Fly casting with ligand sliding and orientational selection supporting complex formation of a GPCR and a middle sized flexible molecule

Scientific Reports, 2022
A GA-guided multidimensional virtual-system coupled molecular dynamics (GA-mD-VcMD) simulation was conducted to elucidate binding mechanisms of a middle-sized flexible molecule, bosentan, to a GPCR protein, human endothelin receptor type B (hETB).
Junichi Higo, Kota Kasahara, Gert-Jan Bekker, Benson Ma, Shun Sakuraba, Shinji Iida, Narutoshi Kamiya, Ikuo Fukuda, Hidetoshi Kono, Yoshifumi Fukunishi, Haruki Nakamura   +10 more
doaj   +1 more source

Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers.

PLoS ONE, 2020
Systemic sclerosis is a disease where microcirculation damage is critical in their beginning and vascular complications have similar pathogenic findings. Digital ulcers are a frequent complication in systemic sclerosis patients and pulmonary hypertension
Ivan Castellví, Carmen Pilar Simeón, Monica Sarmiento, Jordi Casademont, Hèctor Corominas, Vicenç Fonollosa   +5 more
doaj   +1 more source